Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.

[1]  V. Vullo,et al.  Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-γ)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection. , 2017, Clinics and research in hepatology and gastroenterology.

[2]  Daniel L. Popkin,et al.  During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy. , 2016, The Journal of infectious diseases.

[3]  M. Lederman,et al.  Systemic inflammation and liver damage in HIV/hepatitis C virus coinfection , 2016, HIV medicine.

[4]  M. Lederman,et al.  Inflammation Perturbs the IL-7 Axis, Promoting Senescence and Exhaustion that Broadly Characterize Immune Failure in Treated HIV Infection , 2016, Journal of acquired immune deficiency syndromes.

[5]  Michael M. Lederman,et al.  Soluble CD14 is a nonspecific marker of monocyte activation , 2015, AIDS.

[6]  M. Lederman,et al.  Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. , 2014, The Journal of infectious diseases.

[7]  M. Lederman,et al.  Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. , 2014, The Journal of infectious diseases.

[8]  D. Dolfi,et al.  Circulating CXCR5+PD-1+ Response Predicts Influenza Vaccine Antibody Responses in Young Adults but not Elderly Adults , 2014, The Journal of Immunology.

[9]  D. Anthony,et al.  Older Age Is Associated with Peripheral Blood Expansion of Naïve B Cells in HIV-Infected Subjects on Antiretroviral Therapy , 2014, PloS one.

[10]  M. Lederman,et al.  Inflammatory cytokines drive CD4+ T-cell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease. , 2014, The Journal of infectious diseases.

[11]  B. Bibby,et al.  Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C , 2014, Hepatology.

[12]  P. Böelle,et al.  Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Shu-Min Lin,et al.  KLRG1 Impairs CD4+ T Cell Responses via p16ink4a and p27kip1 Pathways: Role in Hepatitis B Vaccine Failure in Individuals with Hepatitis C Virus Infection , 2014, The Journal of Immunology.

[14]  M. Lederman,et al.  Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine , 2013, PloS one.

[15]  M. Lederman,et al.  Plasma Proteome Analysis Reveals Overlapping, yet Distinct Mechanisms of Immune Activation in Chronic HCV and HIV Infections , 2013, Journal of acquired immune deficiency syndromes.

[16]  C. Weyand,et al.  Understanding immunosenescence to improve responses to vaccines , 2013, Nature Immunology.

[17]  J. Moorman,et al.  Immune Exhaustion and Immune Senescence: Two Distinct Pathways for HBV Vaccine Failure During HCV and/or HIV Infection , 2013, Archivum Immunologiae et Therapiae Experimentalis.

[18]  F. Barré-Sinoussi,et al.  Acute Plasma Biomarkers of T Cell Activation Set-Point Levels and of Disease Progression in HIV-1 Infection , 2012, PloS one.

[19]  E. Rosenberg,et al.  Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. , 2011, The Journal of infectious diseases.

[20]  M. Lederman,et al.  Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. , 2011, The Journal of infectious diseases.

[21]  D. Kleiner,et al.  Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. , 2011, Gastroenterology.

[22]  David L. Thomas,et al.  CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. , 2011, The Journal of infectious diseases.

[23]  E. Rosenberg,et al.  Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. , 2011, The Journal of infectious diseases.

[24]  L. Ni,et al.  Impaired hepatitis B vaccine responses during chronic hepatitis C infection: involvement of the PD-1 pathway in regulating CD4(+) T cell responses. , 2011, Vaccine.

[25]  S. Crotty,et al.  Follicular helper CD4 T cells (TFH). , 2011, Annual review of immunology.

[26]  S. Lewin,et al.  Plasma levels of soluble CD14 independently predict mortality in HIV infection. , 2011, The Journal of infectious diseases.

[27]  D. Anthony,et al.  Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection. , 2011, The Journal of infectious diseases.

[28]  F. Aoudjit,et al.  Interleukin‐7 promotes the survival of human CD4+ effector/memory T cells by up‐regulating Bcl‐2 proteins and activating the JAK/STAT signalling pathway , 2010, Immunology.

[29]  M. Lederman,et al.  Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. , 2010, The Journal of infectious diseases.

[30]  Veronica D. Gonzalez,et al.  Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. , 2010, Clinical immunology.

[31]  A. Geretti,et al.  Immunization for HIV-positive individuals , 2010, Current opinion in infectious diseases.

[32]  Marianthi Markatou,et al.  Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. , 2009, The Journal of infectious diseases.

[33]  Philimon N. Gona,et al.  Virologic and Immunologic Correlates With the Magnitude of Antibody Responses to the Hepatitis A Vaccine in HIV-Infected Children on Highly Active Antiretroviral Treatment , 2009, Journal of acquired immune deficiency syndromes.

[34]  K. H. Hullsiek,et al.  Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. , 2009, Vaccine.

[35]  A. Hatzakis,et al.  Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  L. Chiriboga,et al.  Intrahepatic levels of CXCR3‐associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C , 2008, Hepatology.

[37]  Lewis H Kuller,et al.  Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.

[38]  M. Lederman,et al.  The lymph node in HIV pathogenesis. , 2008, Seminars in immunology.

[39]  A. Neumann,et al.  Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. , 2006, The Journal of infectious diseases.

[40]  C. Gabay,et al.  CD14 Is an Acute-Phase Protein1 , 2004, The Journal of Immunology.

[41]  M. Dziejman,et al.  IFN-γ-Inducible Protein 10 (IP-10; CXCL10)-Deficient Mice Reveal a Role for IP-10 in Effector T Cell Generation and Trafficking1 , 2002, The Journal of Immunology.

[42]  T. Okanoue,et al.  Clinical significance of elevated serum interferon‐ inducible protein‐10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels , 2001, Journal of viral hepatitis.

[43]  Dong-er Zhang,et al.  Hepatocytes Contribute to Soluble CD14 Production, and CD14 Expression Is Differentially Regulated in Hepatocytes and Monocytes* , 2000, The Journal of Biological Chemistry.

[44]  U. Liebert,et al.  Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C , 2000, Hepatology.

[45]  J V Giorgi,et al.  Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. , 1999, The Journal of infectious diseases.

[46]  P. Kingsley,et al.  Characterization of human endotoxin lipopolysaccharide receptor CD14 expression in transgenic mice. , 1999, Journal of immunology.

[47]  T. Ferraro,et al.  Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. , 1998, The New England journal of medicine.

[48]  A. Luster,et al.  Regulated production of the interferon‐γ‐inducible protein−10 (IP‐10) chemokine by human neutrophils , 1997 .

[49]  C. Mengoli,et al.  Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. , 2009, Vaccine.

[50]  J. Buxton,et al.  Hepatitis A and hepatitis B vaccination responses in persons with chronic hepatitis C infections: A review of the evidence and current recommendations. , 2008, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.